US approves anti-malarial drug to treat COVID-19, says Donald Trump

But the FDA Commissioner Stephen Hahn later indicated that, while the drug has not yet been formally approved, access to it was being expanded so that authorities could gather more data

Donald Trump
President Donald Trump speaks in an address to the nation from the Oval Office at the White House about the coronavirus
Agencies
2 min read Last Updated : Mar 20 2020 | 3:03 AM IST
The US has approved the anti-malarial drug chloroquine for use as a treatment against the new coronavirus, President Donald Trump said on Thursday.
 
“We're going to be able to make that drug available almost immediately, and that's where the FDA (Food and Drug Administration) has been so great," Trump told reporters.
 
“They've gone through the approval process — it's been approved. They took it down from many, many months to immediate. So we're going to be able to make that drug available by prescription.”
 

Also Read

But the FDA Commissioner Stephen Hahn later indicated that, while the drug has not yet been formally approved, access to it was being expanded so that authorities could gather more data.
 
This is known as “compassionate use.” “If there is an experimental drug that is potentially available, a doctor could ask for that drug to be used in a patient. We have criteria for that and very speedy approval for that,” said Hahn.
 
"As an example, many Americans have read studies and heard media reports about this drug chloroquine, which is an anti-malarial drug.
 
"It's already approved, as the president said, for the treatment of malaria as well as an arthritis condition.
 
"That's a drug that the president directed us to take a closer look at, as to whether an expanded use approach to that could be done to actually see if that benefits patients." Chloroquine is a synthetic form of quinine, which has been used to treat malaria since the 1940s.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusUnited StatesUS President TrumpMalaria vaccineUSFDA

Next Story